

October 20, 2016



## Pieris Announces Presentations at Upcoming R&D Conferences

BOSTON, MA -- (Marketwired) -- 10/20/16 -- **Pieris Pharmaceuticals, Inc.** (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary [Anticalin](#)<sup>®</sup> technology platform for cancer and other diseases, announced today presentations at two upcoming R&D conferences focused on immuno-oncology.

The details for each presentation are as follows:

*American Association of Cancer Research (AACR) Special Conference on Tumor Immunology and Immunotherapy*, Boston Marriott Copley Plaza, Boston, MA, October 20 - 23, 2016

*Presentation Time:* Friday, October 21, 2016, 5:15 pm-7:45 pm, Back Bay room

*Presentation:* A poster presentation entitled, "Costimulatory T-cell engagement by PRS-343, a CD137 (4-1BB)/HER2 bispecific, leads to tumor growth inhibition and CD8(+) T cell expansion in a humanized mouse model."

*Society of Immunotherapy of Cancer (SITC)*, Gaylord National Hotel & Convention Center, National Harbor, Maryland, November 9 - 13, 2016

*Oral Presentation:* An oral presentation entitled "PRS-343, a CD137 (4-1BB)/HER2 Bispecific" will be given on Wednesday, November 9, 2016, 11:50 am

*Poster Presentation:* New Cancer Immunotherapy -- A poster presentation will be presented on Saturday, November 12, 2016, 11:45 am - 1:00 pm and 6:45 pm - 8:00 pm

### ***About Pieris***

Pieris Pharmaceuticals is a clinical-stage biotechnology company that discovers and develops Anticalin<sup>®</sup> protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of protein therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin<sup>®</sup> is a registered trademark of Pieris. For more information visit [www.pieris.com](http://www.pieris.com).

Company Contact:

Pieris Pharmaceuticals, Inc.  
Darlene Deptula-Hicks  
SVP & Chief Financial Officer  
1-603-553-5803  
[deptula@pieris.com](mailto:deptula@pieris.com)

Investor Relations Contact:  
The Trout Group  
Thomas Hoffmann  
1-646-378-2931  
[thoffmann@troutgroup.com](mailto:thoffmann@troutgroup.com)

Media Inquiries:  
Gretchen Schweitzer  
+49 172 861 8540  
[gschweitzer@macbiocom.com](mailto:gschweitzer@macbiocom.com)

Source: Pieris Pharmaceuticals, Inc.